Sodium Oxybate
| Evidence Level: L2 | Predicted Indications: 6 |
Table of Contents
Sodium Oxybate: From Narcolepsy to Insomnia
One-Sentence Summary
Sodium oxybate is a central nervous system depressant, originally used to treat narcolepsy (including narcolepsy with cataplexy). The TxGNN model predicts it may be effective for insomnia, with 3 registered clinical trials and 12 publications currently linked to this direction. Only one of these trials directly tests insomnia, and it is a small Phase 2 study.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy (narcolepsy with cataplexy, narcolepsy without cataplexy) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, sodium oxybate (gamma-hydroxybutyrate, GHB) acts as an agonist at GABA-B and GHB receptors. Its efficacy in narcolepsy has been established, and it may be mechanistically applicable to insomnia.
Sodium oxybate increases slow-wave sleep and consolidates sleep architecture. It is established in narcolepsy, where nighttime sleep is fragmented. Because insomnia involves difficulty initiating or maintaining sleep, this effect is plausibly relevant. A randomized Phase 2 trial has compared it directly with zolpidem in chronic insomnia.
There are important cautions. The drug carries CNS and respiratory depression risk, abuse and misuse potential, and many interactions with sedatives and alcohol. In a common, non-orphan condition such as insomnia, these risks are hard to justify without strong efficacy data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00383643 | Phase 2 | Completed | 48 | Randomized, double-blind, placebo-controlled comparison of sodium oxybate (Xyrem) and zolpidem in chronic insomnia. Directly relevant, but results are not available in the compiled data. |
| NCT00594256 | Phase 2 | Completed | 8 | Open-label pilot of add-on Xyrem for schizophrenia and associated sleep disturbance. Different population, very small, no control arm: weak indirect support. |
| NCT01584934 | Phase 4 | Withdrawn | 0 | Planned placebo-controlled crossover trial in chronic fatigue syndrome. Withdrawn with no participants, so it provides no data. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21476957 | 2011 | Review | Curr Pharm Des | Reviews sodium oxybate and baclofen in sleep disorders. GABA-B agonists reduce sleep onset latency and increase sleep consolidation and slow-wave sleep. |
| 19116896 | 2009 | RCT | Arthritis Rheum | Randomized, double-blind, placebo-controlled trial of sodium oxybate for pain and function in fibromyalgia. |
| 18852348 | 2008 | Open-label study | Arch Neurol | Open-label polysomnographic study of sodium oxybate for excessive daytime sleepiness in Parkinson disease. |
| 19698899 | 2009 | Review | Clin Ther | Tolerability and abuse liability of GHB for insomnia in patients with schizophrenia. |
| 15586785 | 2004 | Pilot study | Sleep | Effect of nighttime sodium oxybate on sleep architecture in narcolepsy. |
| 31526967 | 2019 | Case report | Sleep Med | Sodium oxybate used in a severely sleep-deprived child with EBV encephalitis and a lesion of the sleep-wake regulation system. |
| 40120323 | 2025 | Cohort | J Clin Neurosci | Treatment patterns of patients with narcolepsy treated with immediate-release sodium oxybate. |
| 26171909 | 2015 | Systematic review | Cochrane Database Syst Rev | Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in obstructive sleep apnoea (safety-related). |
| 18805301 | 2008 | Review | Rev Neurol | Overview of narcolepsy with cataplexy. |
| 37590830 | 2023 | Review | Continuum | Pediatric sleep disorders, including insomnia and narcolepsy. |
Most of this literature is general review material or concerns other conditions. Primary efficacy data in insomnia are lacking.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02268272 | XYREM | Not specified | Not specified |
| 02538237 | XYWAV | Not specified | Not specified |
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): hypertension, epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease, substance abuse/dependence, substance-related disorder, obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome, respiratory failure, succinic semialdehyde dehydrogenase deficiency, and parasomnia.
- Drug Interactions: 48 interactions were identified. Major interactions include ethanol, opioids (morphine, codeine, hydrocodone, opium), cannabinoids (dronabinol, nabilone), sedating antihistamines (promethazine, chlorpheniramine, brompheniramine, carbinoxamine, acrivastine), bupropion, fenfluramine, metoclopramide, and sibutramine. Moderate interactions include diazoxide, amyl nitrite, and phentolamine.
- Literature signals: case reports describe sleep-related eating disorder, restless legs syndrome, and intolerance linked to sodium oxybate. Reviews also highlight abuse liability.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The only direct evidence is one small Phase 2 trial (n=48) against zolpidem, with no results available, and the other literature is mostly indirect. Sodium oxybate’s risks (CNS and respiratory depression, abuse potential, extensive sedative and alcohol interactions) are hard to justify in a common condition such as insomnia without stronger efficacy data.
To proceed, the following is needed:
- Published results of NCT00383643, and ideally larger Phase 3 trials in insomnia
- The Health Canada package insert, including approved indications, warnings, and contraindications
- Mechanism of action data
- A risk-benefit and abuse-mitigation assessment for a non-orphan population
- Other predicted indications (sleep disorder of initiating and maintaining sleep, restless legs syndrome, and others) have little or no supporting evidence. Restless legs syndrome even shows a possible harm signal, so these are not recommended for pursuit.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.